2025 almost felt like pharma pressed a reset button on dealmaking. Money moved in patches, a handful of blockbuster deals grabbed headlines and reshaped competitive positions, while the broader market kept its cautionary posture. If you follow the industry, two impressions stand out: (1) big... Continue reading
Return to previous page